Sentante

What Sentante does

Sentante (legal entity UAB Inovatyvi Medicina) is a Lithuanian medical device company founded in 2017 that develops a haptic endovascular robotic platform enabling teleoperated vascular interventions with authentic force feedback. The system consists of a bedside robotic unit that mirrors the physician's hand movements to manipulate standard guidewires (.014" to .035") and catheters (2Fr to 8Fr), a radiation-free remote control workstation with integrated visualization, and single-use disposable sterile cassettes branded Sentacles that ensure a sterile interface with off-the-shelf endovascular devices. The platform runs on NVIDIA Jetson AGX hardware and the NVIDIA Isaac for Healthcare development stack, capturing kinematic and resistance data from each procedure to support machine-learning-assisted clinical decision support. Clinical evidence includes the completed ESSENTIAL first-in-human trial (NCT06537947) at Pauls Stradiņš Clinical University Hospital in Riga (10 patients, 21 fully robotic procedures, 100% technical success, zero radiation exposure to staff) and a world-first transatlantic remote stroke thrombectomy demonstrated in late 2025 with 120 ms latency.

The company operates a razor-and-blade commercial model: capital equipment sales of the robotic platform to hospitals (with a Clinical Sales Manager role supporting field sales and KOL engagement) plus recurring revenue from Sentacles consumables. The Sentante Digital Inflator, launched alongside the platform in May 2026, adds a complementary product for precision-controlled balloon inflation. Target use cases span peripheral vascular interventions (initial commercial focus), remote mechanical neurothrombectomy for acute ischemic stroke (FDA Breakthrough Designation, September 2025), and cardiovascular/electrophysiology procedures. The company received CE mark approval in May 2026 enabling European Economic Area commercialization, with FDA TAP Program acceptance (February 2026) supporting the US regulatory pathway. Customers to date are clinical trial and demonstration sites (Pauls Stradiņš Hospital, Houston Methodist, Baptist Health Jacksonville, Veranex) rather than paying accounts, reflecting the pre-commercial stage of the business.

Sentante is headquartered in Kaunas, Lithuania, employs 11–50 people, and has raised approximately €6M in seed equity (December 2023, led by Practica Capital with EIC Fund participation) plus roughly €4.16M in EU co-funded grants across two projects. The leadership team is co-founder-led (CEO Edvardas Satkauskas; CMO Dr. Tomas Baltrunas, a practicing vascular surgeon), with a Medical Advisory Board including KOLs such as Dr. Ricardo Hanel, Dr. Peter Schneider, Dr. David Liebeskind, and Dr. Michael Jaff. Strategic technology and clinical partners include NVIDIA, Ericsson (network connectivity for tele-surgery), University of Dundee (global WIST training center), and Veranex (GLP study facility).

Name

Sentante

Legal name

UAB Inovatyvi Medicina

Website

https://sentante.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Sentante is a Lithuanian medical device company developing a haptic endovascular robotic platform that enables physicians to perform vascular procedures remotely with authentic force feedback, using standard catheters and guidewires plus disposable sterile cassettes. The system targets hospitals and interventional specialists across peripheral vascular, neurovascular stroke, and cardiovascular procedures, with European commercialization underway after CE mark approval in May 2026.

Ownership category

akta.pro rank

Product category

Surgical Robotics - Endovascular Robotic Systems

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

Keywords

• Endovascular robotic systems
• Remote surgical robotics
• Haptic force feedback
• Interventional radiology robotics
• Cath lab automation

Headquarters

HQ city

Kaunas

HQ country

Lithuania

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. Robotic Platform Hardware Sales: Sale of the Sentante robotic system including bedside unit and control workstation to hospitals and healthcare systems. Capital equipment sale model typical of medical device industry.
2. Sentacles (Disposable Cassettes): Single-use sterile cassettes (Sentacles) required for each procedure. Razor-and-blade model providing recurring revenue from consumables. Estimated market of more than 3,000 cath labs in EU performing over 200,000 endovascular embolization procedures annually.
3. Digital Inflator Device: Precision-controlled digital inflator system that replaces traditional manual indeflator used in endovascular procedures such as angioplasty and stent deployment. Additional product in the portfolio for commercial launch.
4. Clinical Training and Support Services: Technical training sessions for physicians, nurses, and technicians on robotic catheter and guidewire manipulation. Intraoperative guidance and troubleshooting during live cases. Professional services supporting system adoption.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Core offering

Sentante develops and manufactures a haptic, device-agnostic endovascular robotic platform that allows physicians to perform minimally invasive vascular procedures remotely while receiving real tactile force feedback. The platform comprises a bedside robotic unit, an ergonomically designed remote control workstation, and single-use sterile disposable cassettes (Sentacles), with a complementary precision-controlled digital inflator and a stroke-specific SENTANTE Stroke System configuration. The system is sold to hospitals and healthcare systems for use in peripheral vascular, neurovascular, and cardiovascular interventions.

Differentiator

Problem solved

Functional benefit

Brands

• SENTANTE Stroke System: FDA-designated robotic system for remote delivery and manipulation of endovascular devices for stroke thrombectomy
• Sentacles

Products and services

• Sentante Endovascular Robotic System A haptic, device-agnostic endovascular robotic platform that enables clinicians to perform complex vascular procedures remotely with full tactile feedback. The system comprises a bedside robotic unit, an ergonomically designed remote control workstation, and single-use Sentacles cassettes, and supports peripheral, neurovascular, and cardiovascular interventions using standard guidewires (.014 to .035) and catheters (2Fr to 8Fr). It is sold to hospitals and healthcare systems.
• Sentacles (Disposable Sterile Cassettes) Single-use disposable sterile cassettes required for each Sentante robotic procedure. They create a sterile interface between the bedside robot and standard guidewires and catheters, supporting the razor-and-blade recurring revenue model.
• Sentante Digital Inflator A precision-controlled digital inflator system that replaces traditional manual inflators used in endovascular procedures such as angioplasty and stent deployment, with remote-controlled capability for use during robotic procedures.
• SENTANTE Stroke System FDA-designated stroke-specific configuration of the Sentante endovascular robotic platform for remote mechanical neurothrombectomy in acute ischemic stroke patients at hospitals lacking local thrombectomy capability or timely transfer options.

Quantifiable outcome

• 100% technical success rate in ESSENTIAL clinical trial (NCT06537947)
• +6 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered core, major, strategic and supporting.

• U.S. Food and Drug Administration (FDA)coreOthers · 13 February 2026FDA granted Breakthrough Device Designation September 2025 and accepted Sentante into Total Product Life Cycle (TAP) Advisory Program February 2026. Only endovascular robotic system with this recognition for remote stroke thrombectomy.
• VeranexmajorImplementation/ SI/ Consulting Partner · 12 December 2025GLP study facility in Paris where Sentante conducted 24 remote stroke thrombectomy procedures on live animal subjects from three continents. Veranex provided expertise and support during the intensive three-day study.
• University of DundeecoreStrategic or Co-development Partner · 11 November 2025World's first transatlantic robotic thrombectomy performed at University's Image Guided Therapy Research Facility (IGTRF). University of Dundee is official global training centre of World Federation for Interventional Stroke Treatment (WIST). Housing unique surgical environment with human models for research and device testing.
• Baptist Health JacksonvillecoreStrategic or Co-development Partner · 11 November 2025Dr. Ricardo Hanel at Baptist Health performed the transatlantic remote thrombectomy procedure from Jacksonville, Florida. Key clinical collaborator for stroke system development.
• Ericsson (Mischa Dohler, VP Emerging Technologies)strategicTechnology or Integration · 11 November 2025Collaboration on network performance and latency over transatlantic link. Multi-path connectivity established to maintain stable, secure connection for mission-critical remote surgical use.
• NVIDIAstrategicTechnology or Integration · 11 November 2025Sentante integrated NVIDIA Jetson AGX platform into latest generation of endovascular robot. Member of NVIDIA Inception program for startups. Among first to develop on NVIDIA Isaac for Healthcare platform for AI-powered medical robots.
• iVascularsupportingTechnology or Integration · 13 June 2025Provided neuro devices for first fully robotic remote endovascular stroke thrombectomy in animal model. 1600+ km distance between operator in Kaunas and procedure in Paris.
• Pauls Stradiņš Clinical University HospitalmajorStrategic or Co-development Partner · 31 July 2024First-in-human clinical trial site in Riga, Latvia. Prof. Dainis Krievins led 10 patients through 21 fully robotic peripheral endovascular procedures. Critical for regulatory clearance data.
• Telemedicina JSCsupportingStrategic or Co-development Partner · 27 June 2024Joint project for Remote-Controlled Digital Inflator for Endovascular Instruments (Project No. 02-019-K-0067). Total project value EUR 1,127,336 with EUR 871,464 EU funding. Sentante collaborating on digital inflator development.
• Card79 (Afshin Mehin, Levi Joo)supportingTechnology or Integration · 23 March 2023Design collaboration to develop bold and modern design concept for Sentante. Card79 team visited office for collaborative creative session. Their work contributed to iF Design Award 2025 recognition.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Stereotaxis: Stereotaxis develops robotic magnetic navigation systems for cardiac and endovascular interventions, directly competing with Sentante in robotic vascular procedures. Both target electrophysiology and structural heart applications with remotely-controlled catheter manipulation technology.
• Corindus (Siemens Healthineers): Corindus, a Siemens Healthineers company, develops the CorPath GRX robotic system for percutaneous coronary and peripheral vascular interventions. It is the closest direct competitor to Sentante in endovascular robotics, currently focusing on coronary interventions with planned neurovascular expansion.
• Penumbra: Penumbra is a leader in mechanical thrombectomy for acute ischemic stroke and peripheral vascular procedures. While not robotic, Penumbra's stroke thrombectomy franchise directly overlaps with Sentante's SENTANTE Stroke System indication and represents both a competitor and potential strategic acquirer.
• Robocath: Robocath develops the R-One robotic platform for percutaneous coronary interventions. A France-based cardiovascular robotics company with CE Mark and emerging European commercial presence that directly competes with Sentante in robotic vascular procedures.

Emerging players

• MicroPort MedBot: MicroPort's MedBot division develops surgical and vascular robotic systems, including the Toumai laparoscopic robot with expansion into endovascular applications. A well-capitalized emerging player from Asia targeting the same robotic surgery category with broader procedure coverage.
• Vicarious Surgical: Vicarious Surgical is developing next-generation surgical robotics combining virtual reality and AI. While focused on laparoscopic applications, its approach to making complex procedures more accessible through technology parallels Sentante's mission to expand access via remote robotics.

Broad incumbents

• Intuitive Surgical: Intuitive Surgical is the dominant surgical robotics incumbent with the da Vinci platform. While focused on laparoscopic surgery rather than endovascular, Intuitive has the capital, hospital relationships, and R&D resources to enter endovascular robotics, representing the most significant long-term competitive threat.
• Medtronic: Medtronic is a leading medical device incumbent with significant presence in stroke thrombectomy (Solitaire stent retriever), cardiac interventions, and a Hugo surgical robotics platform. As a broad incumbent with the resources to develop or acquire endovascular robotic technology, Medtronic represents a major potential competitor or acquirer.
• Stryker: Stryker operates the Mako surgical robotics platform for orthopedics with growing presence in neurovascular devices. As a broad incumbent with established hospital sales channels and significant R&D budget, Stryker could expand into endovascular robotics or acquire a player like Sentante.

Others

• NVIDIA (Healthcare): NVIDIA provides the Isaac for Healthcare platform and Jetson AGX hardware that powers Sentante's AI capabilities. As a strategic technology partner rather than competitor, NVIDIA's healthcare AI ecosystem developments directly enable and shape Sentante's AI roadmap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/inovatyvi-medicina

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sentante